Brokerages expect Kalvista Pharmaceuticals Inc (NASDAQ:KALV) to report earnings of ($0.56) per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Kalvista Pharmaceuticals’ earnings. The highest EPS estimate is ($0.37) and the lowest is ($0.63). Kalvista Pharmaceuticals posted earnings of ($0.23) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 143.5%. The firm is scheduled to report its next earnings results on Thursday, March 12th.
According to Zacks, analysts expect that Kalvista Pharmaceuticals will report full-year earnings of ($1.63) per share for the current year, with EPS estimates ranging from ($2.26) to ($0.63). For the next fiscal year, analysts forecast that the company will post earnings of ($2.74) per share, with EPS estimates ranging from ($3.75) to ($1.57). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Kalvista Pharmaceuticals.
Kalvista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Tuesday, December 3rd. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.22. Kalvista Pharmaceuticals had a negative net margin of 182.37% and a negative return on equity of 25.70%. The firm had revenue of $3.92 million during the quarter, compared to the consensus estimate of $3.23 million.
In related news, insider Christopher Yea sold 3,010 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $17.05, for a total value of $51,320.50. Following the completion of the transaction, the insider now directly owns 83,168 shares of the company’s stock, valued at approximately $1,418,014.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Thomas Andrew Crockett sold 5,400 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $17.06, for a total transaction of $92,124.00. Following the completion of the transaction, the chief executive officer now directly owns 248,320 shares of the company’s stock, valued at $4,236,339.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,010 shares of company stock valued at $170,720. 21.60% of the stock is owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC purchased a new stake in Kalvista Pharmaceuticals in the 1st quarter worth approximately $21,036,000. Northern Trust Corp lifted its stake in Kalvista Pharmaceuticals by 80.5% in the 2nd quarter. Northern Trust Corp now owns 73,830 shares of the specialty pharmaceutical company’s stock worth $1,635,000 after purchasing an additional 32,930 shares in the last quarter. BlackRock Inc. lifted its stake in Kalvista Pharmaceuticals by 948.7% in the 2nd quarter. BlackRock Inc. now owns 736,782 shares of the specialty pharmaceutical company’s stock worth $16,320,000 after purchasing an additional 666,525 shares in the last quarter. Vanguard Group Inc. lifted its stake in Kalvista Pharmaceuticals by 47.7% in the 2nd quarter. Vanguard Group Inc. now owns 527,829 shares of the specialty pharmaceutical company’s stock worth $11,692,000 after purchasing an additional 170,439 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Kalvista Pharmaceuticals in the 2nd quarter worth approximately $42,000. 90.59% of the stock is owned by institutional investors.
Shares of Kalvista Pharmaceuticals stock traded down $0.19 on Friday, reaching $13.96. 43,197 shares of the company traded hands, compared to its average volume of 101,478. Kalvista Pharmaceuticals has a 52 week low of $9.86 and a 52 week high of $34.92. The company has a 50 day moving average of $16.21 and a 200 day moving average of $14.52. The firm has a market capitalization of $259.31 million, a PE ratio of -9.50 and a beta of 2.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.31 and a quick ratio of 10.30.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Read More: Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.